Shares of United Therapeutics UTHR surged 33% on Tuesday after it announced positive top-line results from the late-stage TETON-2 study evaluating the nebulized version of Tyvaso (treprostinil) in ...
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 ...
MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH ...
United Therapeutics UTHR reported second-quarter 2025 earnings of $6.41 per share, which missed the Zacks Consensus Estimate of $6.80. However, earnings rose 10% year over year on the back of higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback